Jim Cramer, responding to a viewer's question via Twitter (TWTR - Get Report) on the New York Stock Exchange, says he needs to reevaluate the company. Biogen, one of Cramer's 'Four Horsemen,' disappointed investors by lowering its full-year earnings and sales forecast because it no longer expects its multiple sclerosis drug Tecfidera to grow as expected. While he reconsiders the stock, Cramer stresses that he likes Regeneron (REGN - Get Report), Celgene (CELG - Get Report) and Gilead Sciences (GILD - Get Report) much more than Biogen. Another viewer notes that Inotek Pharmaceuticals (ITEK) just had a positive Phase II meeting with the U.S. Food and Drug Administration (FDA) and asks if the stock is a buy here. Cramer explains that the smart money was already there before the company's meeting with the FDA and that the stock would be too risky for him now.
When it comes to Sprint (S - Get Report), Cramer says the stock is a sell. He says it's a balance sheet issue for Sprint and he believes the company needs to raise a lot of money. He also weighs in on other names in the space like T-Mobile (TMUS - Get Report), AT&T (T - Get Report) and Verizon (VZ - Get Report).
In response to a viewer looking for insight on Ford (F - Get Report), Cramer says forget about it. He notes that Latin America isn't performing well, Europe is only okay and the company doesn't have as big of a presence in China as General Motors (GM - Get Report). With many investors out there may believe auto stocks are peaking, Cramer says that he's not recommending any of them. While his charitable trust portfolio Action Alerts PLUS own shares of General Motors, Cramer reveals that he's uncertain about that.
Lastly, Cramer weighs in on how to play Ambarella (AMBA - Get Report), a stock he says he likes for more than just being a play on GoPro (GPRO). If you have a stock question, tweet it @jimcramer using #CramerQ.